4.2 Article

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match

Journal

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 14, Issue 12, Pages 1334-1340

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2008.09.009

Keywords

Unrelated donor; HLA match; Hematopoietic cell transplantation

Funding

  1. National Cancer Institute [U24-CA76518]
  2. National Institute of Allergy and Infectious Diseases
  3. National Heart, Lung and Blood Institute
  4. Office of Naval Research [NMDP N00014-06-1-0704]
  5. Health Resources and Serices Administration (DHHS)
  6. AABB
  7. Aetna
  8. American Society for Blood and Marrow Transplantation
  9. Amgen, Inc.
  10. Anonymous donation to the Medical College of Wisconsin
  11. Association of Medical Microbiology and Infectious Disease Canada
  12. Astellas Pharma US, Inc.
  13. Baxter International, Inc.
  14. Bayer HealthCare Pharmaceuticals
  15. BloodCenter of Wisconsin
  16. Blue Cross and Blue Shield Association
  17. Bone Marrow Foundation
  18. Canadian Blood and Marrow Transplant Group
  19. Celgene Corporation
  20. CellGenix, GmbH
  21. Centers for Disease Control and Prevention
  22. ClinImmune Labs
  23. CTI Clinical Trial and Consulting Services
  24. Cubist Pharmaceuticals
  25. Cylex Inc.
  26. CytoTherm
  27. DOR BioPharma, Inc.
  28. Dynal Biotech
  29. Invitrogen Company
  30. Enzon Pharmaceuticals, Inc.
  31. European Group for Blood and Marrow Transplantation
  32. Gambro BCT, Inc.
  33. Gamida Cell, Ltd.
  34. Genzyme Corporation, Histogenetics, Inc.
  35. HKS Medical Information Systems
  36. Hospira, Inc.
  37. Infectious Diseases Society of America
  38. Kiadis Pharma
  39. Kirin Brewery Co., Ltd.
  40. Merck Company
  41. The Medical College of Wisconsin
  42. MGI Pharma, Inc.
  43. Michigan Community Blood Centers
  44. Millennium Pharmaceuticals, Inc.
  45. Miller Pharmacal Group
  46. Milliman USA, Inc.
  47. Miller Biotec, Inc.
  48. National Marrow Donor Program
  49. Nature Publishing Group
  50. New York Blood Center
  51. Novartis Oncology
  52. Oncology Nursing Society
  53. Osiris Therapeutics, Inc.
  54. Otsuka Pharmaceutical Development & Commercialization, Inc.
  55. Pall Life Sciences
  56. PDL BioPharma, Inc
  57. Pfizer Inc
  58. Pharmion Corporation
  59. Saladax Biomedical, Inc.
  60. Schering Plough Corporation
  61. Society for Healthcare Epidemiology of America
  62. StemCyte, Inc.
  63. StemSoft Software, Inc.
  64. Sysmex
  65. Teva Pharmaceutical Industries
  66. The Marrow Foundation
  67. THERAKOS, Inc.
  68. Vidacare Corporation
  69. Vion Pharmaceuticals, Inc.
  70. ViraCor Laboratories
  71. ViroPharma, Inc.
  72. Wellpoint, Inc.

Ask authors/readers for more resources

The impact of non-HLA patient factors on the match of the selected unrelated donor (URD) for hematopoietic cell transplantation (HCT) has not been fully evaluated. National Marrow Donor Program (NMDP) data for 7486 transplants using peripheral blood stem cells (PBSCs) or bone marrow from years 2000 to 2005 were evaluated using multivariate logistic regression to identify independent non-HLA patient factors associated with completing a more closely matched URD transplant. Advanced (intermediate- and late-stage) disease was significantly associated with an increased likelihood of transplant using a less-matched (partially matched or mismatched) donor. Additionally, Black patients were 2.83 times, Asian patients 2.05 times, and Hispanic patients 1.73 times more likely to have a less-matched HCT donor than Caucasian patients. Younger patients, HCT at lower volume centers, and in earlier years had significantly higher likelihood of having a less HLA matched URD transplant. Our analysis provides encouraging evidence of HLA matching improvement in recent years. Initiating a patient's URD search early in the disease process, especially for patients from non-Caucasian racial and ethnic groups, will provide the best likelihood for identifying the best available donor and making informed transplant decisions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available